Bill > SB00749

This bill requires the Connecticut Commissioner of Consumer Protection to classify xylazine as a Schedule IV controlled substance. Xylazine is a veterinary sedative and muscle relaxant that has increasingly been found as an adulterant in illicit opioids, particularly fentanyl, which has raised significant public health concerns. By adding xylazine to Schedule IV of the state's controlled substance regulations, the bill aims to create legal mechanisms to control and restrict the unauthorized distribution and use of this drug. Schedule IV substances are defined as drugs with a lower potential for abuse compared to Schedule III substances, but still require regulated handling. This classification will likely enable law enforcement and public health officials to more effectively monitor and potentially reduce the unauthorized presence of xylazine in illegal drug supplies, addressing the growing problem of xylazine's role in the ongoing opioid crisis.

Justice

https://www.cga.ct.gov/asp/cgabillstatus/cgabillstatus.asp?selBillType=Bill&bill_num=SB00749&which_year=2025